As Alzheimer's Pipeline Hits 192 Active Trials, a New Volume Maps the Drug Discovery Science Behind Them
As of early 2026, the Alzheimer’s Association counts 192 active clinical trials evaluating 158 novel therapeutic agents — up from 182 trials and 138 drugs just a year earlier — with eight Phase 3 and 29 Phase 2 studies expected to reach primary completion before the year is out. The pipeline’s center of gravity is shifting, too: on May 14, 2026, Biogen reported topline Phase 2 CELIA results for diranersen, a tau-lowering antisense oligonucleotide that reduced tau pathology and slowed clinical decline, even though it missed its primary endpoint — full data are due at the Alzheimer’s Association International Conference in July 2026. It is the clearest sign yet that amyloid-targeting antibodies like lecanemab and donanemab, now both FDA-approved and Medicare-covered, are no longer the whole story.
Advances in Drug Discovery for Alzheimer’s Disease, Volume 44 in Springer’s Topics in Medicinal Chemistry series, arrives at exactly this moment. Edited by Michael S. Wolfe of the University of Kansas, it is the medicinal-chemistry layer underneath the trial headlines: how γ-secretase modulators and BACE1 inhibitors target amyloid-β, how tau aggregation modulators and molecular chaperones target tau, and — in a closing chapter — how artificial intelligence is being used to repurpose existing compound libraries against new targets faster than conventional discovery allows.
For a working lab or teaching program, the volume does three concrete things: it lets a secretase or tau-aggregation group benchmark its own approach against the current competitive landscape before the next trial readout; it gives drug-discovery teams a structured way to triage compound libraries using the AI-repurposing methods described in the final chapter; and it gives graduate and postdoctoral training programs a single, current reference for how the field’s two defining pathologies are actually being drugged.
For academic and medical research libraries, that combination — mechanism, live pipeline context, and a dedicated AI chapter — makes this a direct addition to core holdings in medicinal chemistry, pharmacology, and neuroscience, not a title to queue for a future acquisitions cycle.
CLNZ Books supplies academic and professional libraries worldwide with current medicinal chemistry and neuroscience titles, backed by institutional invoicing and worldwide shipping.
Q&A
What is the current state of the Alzheimer’s drug discovery pipeline in 2026?
The Alzheimer’s Association counts 192 active trials evaluating 158 novel agents in early 2026, with eight Phase 3 and 29 Phase 2 studies expected to reach primary completion this year.
What is diranersen and why did its Phase 2 results matter?
Diranersen is a tau-lowering antisense oligonucleotide from Biogen; its May 2026 Phase 2 CELIA results showed reduced tau pathology and slowed clinical decline, reinforcing tau as a serious therapeutic target alongside amyloid.
What does Advances in Drug Discovery for Alzheimer’s Disease cover?
It covers amyloid-β-directed therapeutics (secretase modulators and inhibitors), tau-directed therapeutics (aggregation modulators and molecular chaperones), caspase-2 as an emerging target, and AI-driven drug repurposing.
Who edited this volume and what is their background?
It is edited by Michael S. Wolfe, the Mathias P. Mertes Professor of Medicinal Chemistry at the University of Kansas, whose research focuses on the molecular basis of Alzheimer’s disease.
Where can I buy Advances in Drug Discovery for Alzheimer’s Disease?
It is available for order directly through CLNZ Books, with worldwide shipping for academic and professional libraries.